Korean J Pancreas Biliary Tract.  2020 Jul;25(2):107-117. 10.15279/kpba.2020.25.2.107.

Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis

• Ahn DW

• KMID: 2505001
• DOI: http://doi.org/10.15279/kpba.2020.25.2.107

Abstract

Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are immune-mediated chronic liver diseases. PSC is a rare disorder characterized by multi-focal bile duct strictures and progressive liver diseases, in which liver transplantation is required ultimately in most patients. Imaging studies such as magnetic resonance cholangiopancreatography have important role in diagnosis in most cases of PSC. PSC is usually accompanied by inflammatory bowel disease and there is a high risk of cholangiocarcinoma and colorectal cancer in PSC. No medical therapies have been proven to delay progression of PSC. Endoscopic intervention for tissue diagnosis or biliary drainage is frequently required in cases of PSC with dominant stricture, acute cholangitis, or clinically suspected cholangiocarcinoma. PBC is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in endstage biliary cirrhosis requiring liver transplantation. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse in PBC and risk stratification is important to ensure all patients receive a personalised approach to their care. Medical therapy using ursodeoxycholic acid (UDCA) or obeticholic acid (OCA) has an important role to reduce the progression to end-stage liver disease in PBC.

Keyword

원발성 경화성 담관염; 원발성 담즙성 담관염; 담관암; 우르소데옥시콜산; 간이식; Primary sclerosing cholangitis; Primary biliary cholangitis; Cholangiocarcinoma; Ursodeoxycholic acid; Liver transplantation